http://rdf.ncbi.nlm.nih.gov/pubchem/patent/EP-2716764-A1
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_8fb9734f7028cd0900715ab41e0cd11c |
| classificationCPCAdditional | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2710-10321 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2710-10343 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2710-10332 |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K35-761 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N7-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N15-86 |
| classificationIPCAdditional | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12R1-93 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P35-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12N15-861 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K48-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12N15-66 |
| filingDate | 2012-02-29-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_1a735e9347a9fd3eaefe616ab5f5e5dd http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_82e10d73fd5aea8ada9427c6c73b2f54 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_3ad88667204bb707b350e497fea38bb1 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_acec9d2c6aa6bc57f14b5647cefe36ab http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_9a94e8bb1a10878f34f8e37d7f93e053 |
| publicationDate | 2014-04-09-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | EP-2716764-A1 |
| titleOfInvention | Construction and application of mutant type b human adenovirus ad11 having enhanced oncolytic power |
| abstract | A method for constructing type-B recombinant human adenoviral vectors Ad11-5EP and Ad11-5ETel-GFP, and applications thereof. Construction of the adenoviral vector Ad11-5EP utilizes homologous recombination to substitute a 365 bp-long gene upstream segment of the Ad5 E1A coding sequence (comprising the enhancer and promoter of Ad5 E1A) to the corresponding region of type-B human adenovirus subtype 11 Ad11, thereby constructing said vector Ad11-5EP. The method for constructing the type-B recombinant human adenoviral vectorAd11-5ETel-GFP is simultaneous homologous recombination of the genomes of the constructed shuttle vectors pSSENTel, pSSGFP and Ad11-5EP, so as to produce said Ad11-5ETel-GFP. Vector Ad11-5EP possesses a stronger oncolytic effect than the wild-type Ad11, which enhances the power to kill tumor cells. Measurements of tumour growth and tumour clearance rates show that Ad11-5EP effectively reduces tumour growth rates, while the tumour-free ratio among tumour-bearing mice using AdII-5EP is noticeably better than for Ad11. Constructed Ad11-SETel-GFP can be used for treating tumours, or for specific, sensitive and economical detection of tumour cells in circulating blood. |
| priorityDate | 2011-05-31-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
| Predicate | Subject |
|---|---|
| isDiscussedBy | http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID129247857 http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID3429 |
Total number of triples: 27.